Genmab Announces Net Sales of DARZALEX for Q3 2025

Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) for the third quarter of 2025, totaling USD 3,672 million. This includes sales of the subcutaneous product, DARZALEX FASPRO. The U.S. contributed USD 2,088 million, while the rest of the world accounted for USD 1,584 million. Genmab receives royalties on these sales under an exclusive worldwide license with Johnson & Johnson. The company, headquartered in Copenhagen, Denmark, focuses on developing innovative antibody therapeutics to improve patient lives. This announcement also includes forward-looking statements regarding future performance and potential risks.